Efficacy and Safety of ALXN1840 (Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease Efficacy and Safety of ALXN1840 (Administered for 48 Weeks Versus Standard of Care in Participants W ...
A Phase 3, Randomized, Rater-Blinded, Multi-Center Study To Evaluate the Efficacy and Safety of ALXN1840 Administered For 48 Weeks Versus Standard of Care in Patients With Wilson Disease Aged 12 Years and Older A Phase 3, Randomized, Rater-Blinded, Multi-Center Study To Evaluate the Efficacy and Safety of ALXN ...
Wilson Disease
Drug: ALXN1840;Drug: SoCTherapy
Alexion Pharmaceuticals
NULL
Active, not recruiting
12 Years
N/A
All
215
Phase 3
United States;Australia;Austria;Canada;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Israel;Japan;Korea, Republic of;New Zealand;Poland;Russian Federation;Serbia;Singapore;Spain;Taiwan;Turkey;United Kingdom;Belgium;Italy United States;Australia;Austria;Canada;Czechia;Denmark;France;Germany;Hong Kong;Hungary;Israel;Japan ...